I recently emailed Joe Dillon, a US based pharma executive, Neuren's corporate presentation and asked if slide 5 (pipeline) would generate any interest in the industry. His response and link to his profile are below. Nothing ground breaking but its encouraging to see a positive opinion from someone in the industry.
http://www.dilloncapital.com/team.htmHi XXXX,
I would saythese assets would be of great interest to rare disease companies, of whichthere are many these days, provided the MOA/data is pointing to transformativetreatment outcomes that are superior to any other agents currently available orin development.
Best,
Joe
Joe Dillon,Ph.D., MBA
CEO
DillonCapital Strategies
A unit ofSynerphysics Inc.
+1202.255.3780
Ann: Phase 3 trial of trofinetide in Rett syndrome commences, page-45
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B | |||
| Open | High | Low | Value | Volume |
| $20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1378 | $21.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.29 | 218 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |